{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1362544419738589056.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1111/j.1440-1746.2008.05760.x"}},{"identifier":{"@type":"URI","@value":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1440-1746.2008.05760.x"}},{"identifier":{"@type":"URI","@value":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1440-1746.2008.05760.x"}},{"identifier":{"@type":"PMID","@value":"19226381"}}],"dc:title":[{"@value":"Efficacy of entecavir treatment for lamivudine‐resistant hepatitis B over 3 years: Histological improvement or entecavir resistance?"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:title>Abstract</jats:title><jats:p><jats:bold>Background and Aims: </jats:bold> Long‐term lamivudine therapy is required for patients with chronic hepatitis B, because hepatitis reappears frequently after it has withdrawn. However, hepatitis B virus (HBV) mutants resistant to lamivudine emerge frequently accompanied by breakthrough hepatitis.</jats:p><jats:p><jats:bold>Methods: </jats:bold> Effects of entecavir were evaluated in 19 patients who had developed breakthrough hepatitis during lamivudine therapy for longer than 5 years. This study is a subgroup analysis of a previously reported study. Entecavir, in either 0.5 or 1.0 mg/day doses, was given to 10 and nine patients for 52 weeks, respectively, and then all received 1.0 mg/day entecavir for an additional 68–92 weeks.</jats:p><jats:p><jats:bold>Results: </jats:bold> There were no differences in biochemical and virological responses in the two groups of patients with respect to the two different initial doses of entecavir. Serum levels of alanine aminotransferase were normalized in 17 (90%) patients, and hepatitis B e antigen (HBeAg) disappeared from the serum in two (14%) of the 14 patients who were HBeAg‐positive before. Furthermore, a decrease in histological activity index score greater than 2 points was achieved in nine of the 11 (82%) patients in whom annual liver biopsies were performed during 3 years while they received entecavir. HBV mutants resistant to entecavir emerged in five of the 19 (26%) patients, and hepatitis flare occurred in two of them (40%).</jats:p><jats:p><jats:bold>Conclusion: </jats:bold> Entecavir in the long term would be useful for histological improvement of breakthrough hepatitis induced by lamivudine‐resistant HBV mutants in patients with chronic hepatitis B. However, the relatively high rate of entecavir resistance is a concern, and other strategies need to be considered when available.</jats:p>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1382544419738589068","@type":"Researcher","foaf:name":[{"@value":"Yoshiyuki Suzuki"}]},{"@id":"https://cir.nii.ac.jp/crid/1382544419738589065","@type":"Researcher","foaf:name":[{"@value":"Fumitaka Suzuki"}]},{"@id":"https://cir.nii.ac.jp/crid/1382544419738589056","@type":"Researcher","foaf:name":[{"@value":"Yusuke Kawamura"}]},{"@id":"https://cir.nii.ac.jp/crid/1382544419738589062","@type":"Researcher","foaf:name":[{"@value":"Hiromi Yatsuji"}]},{"@id":"https://cir.nii.ac.jp/crid/1382544419738589057","@type":"Researcher","foaf:name":[{"@value":"Hitomi Sezaki"}]},{"@id":"https://cir.nii.ac.jp/crid/1382544419738589066","@type":"Researcher","foaf:name":[{"@value":"Tetsuya Hosaka"}]},{"@id":"https://cir.nii.ac.jp/crid/1382544419738589067","@type":"Researcher","foaf:name":[{"@value":"Norio Akuta"}]},{"@id":"https://cir.nii.ac.jp/crid/1382544419738589058","@type":"Researcher","foaf:name":[{"@value":"Masahiro Kobayashi"}]},{"@id":"https://cir.nii.ac.jp/crid/1382544419738589063","@type":"Researcher","foaf:name":[{"@value":"Satoshi Saitoh"}]},{"@id":"https://cir.nii.ac.jp/crid/1382544419738589064","@type":"Researcher","foaf:name":[{"@value":"Yasuji Arase"}]},{"@id":"https://cir.nii.ac.jp/crid/1382544419738589184","@type":"Researcher","foaf:name":[{"@value":"Kenji Ikeda"}]},{"@id":"https://cir.nii.ac.jp/crid/1382544419738589059","@type":"Researcher","foaf:name":[{"@value":"Mariko Kobayashi"}]},{"@id":"https://cir.nii.ac.jp/crid/1382544419738589061","@type":"Researcher","foaf:name":[{"@value":"Yuzo Miyakawa"}]},{"@id":"https://cir.nii.ac.jp/crid/1382544419738589060","@type":"Researcher","foaf:name":[{"@value":"Hiromitsu Kumada"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"08159319"},{"@type":"EISSN","@value":"14401746"}],"prism:publicationName":[{"@value":"Journal of Gastroenterology and Hepatology"}],"dc:publisher":[{"@value":"Wiley"}],"prism:publicationDate":"2009-03","prism:volume":"24","prism:number":"3","prism:startingPage":"429","prism:endingPage":"435"},"reviewed":"false","dc:rights":["http://onlinelibrary.wiley.com/termsAndConditions#vor"],"url":[{"@id":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1440-1746.2008.05760.x"},{"@id":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1440-1746.2008.05760.x"}],"createdAt":"2009-02-16","modifiedAt":"2023-10-15","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=Adult","dc:title":"Adult"},{"@id":"https://cir.nii.ac.jp/all?q=Male","dc:title":"Male"},{"@id":"https://cir.nii.ac.jp/all?q=Hepatitis%20B%20virus","dc:title":"Hepatitis B virus"},{"@id":"https://cir.nii.ac.jp/all?q=Guanine","dc:title":"Guanine"},{"@id":"https://cir.nii.ac.jp/all?q=Time%20Factors","dc:title":"Time Factors"},{"@id":"https://cir.nii.ac.jp/all?q=Antiviral%20Agents","dc:title":"Antiviral Agents"},{"@id":"https://cir.nii.ac.jp/all?q=Drug%20Administration%20Schedule","dc:title":"Drug Administration Schedule"},{"@id":"https://cir.nii.ac.jp/all?q=Hepatitis%20B,%20Chronic","dc:title":"Hepatitis B, Chronic"},{"@id":"https://cir.nii.ac.jp/all?q=Drug%20Resistance,%20Multiple,%20Viral","dc:title":"Drug Resistance, Multiple, Viral"},{"@id":"https://cir.nii.ac.jp/all?q=Japan","dc:title":"Japan"},{"@id":"https://cir.nii.ac.jp/all?q=Recurrence","dc:title":"Recurrence"},{"@id":"https://cir.nii.ac.jp/all?q=Humans","dc:title":"Humans"},{"@id":"https://cir.nii.ac.jp/all?q=Hepatitis%20B%20e%20Antigens","dc:title":"Hepatitis B e Antigens"},{"@id":"https://cir.nii.ac.jp/all?q=Aged","dc:title":"Aged"},{"@id":"https://cir.nii.ac.jp/all?q=Alanine%20Transaminase","dc:title":"Alanine Transaminase"},{"@id":"https://cir.nii.ac.jp/all?q=Middle%20Aged","dc:title":"Middle Aged"},{"@id":"https://cir.nii.ac.jp/all?q=Treatment%20Outcome","dc:title":"Treatment Outcome"},{"@id":"https://cir.nii.ac.jp/all?q=Liver","dc:title":"Liver"},{"@id":"https://cir.nii.ac.jp/all?q=Lamivudine","dc:title":"Lamivudine"},{"@id":"https://cir.nii.ac.jp/all?q=DNA,%20Viral","dc:title":"DNA, Viral"},{"@id":"https://cir.nii.ac.jp/all?q=Mutation","dc:title":"Mutation"},{"@id":"https://cir.nii.ac.jp/all?q=Female","dc:title":"Female"}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360285711733152384","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Screening for and management of hepatitis B virus reactivation in patients treated with anti-B-cell therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565168116348928","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"JSH Guidelines for the Management of Hepatitis B Virus Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567185710649216","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Recommendation of lamivudine‐to‐entecavir switching treatment in chronic hepatitis B responders: Randomized controlled trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679771619840","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Two cases of acute hepatitis due to hepatitis E virus that are indigenous to Kitakyushu: a case report"},{"@language":"ja","@value":"北九州に土着したE型肝炎ウイルス株による急性肝炎の2例"},{"@value":"B型肝炎治療ガイドライン(第1.1版)"},{"@language":"ja-Kana","@value":"Bガタ カンエン チリョウ ガイドライン(ダイ1.1ハン)"},{"@language":"ja-Kana","@value":"キタキュウシュウ ニ ドチャク シタ Eガタ カンエンウイルスカブ ニ ヨル キュウセイ カンエン ノ 2レイ"},{"@value":"Guidelines for the management of hepatitis B virus infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679771637120","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"ETV耐性変異（rtA186T）によりviral breakthroughを生じたB型慢性肝炎の1例"},{"@language":"en","@value":"A case of chronic hepatitis B detectable a entecavir resistance mutation (rtA186T)"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282681424647296","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"adefovirの減量と経口リン製剤が有効であった病的尺骨骨折を伴うFanconi症候群の1例"},{"@language":"en","@value":"A Case of Fanconi's Syndrome with Pathological Ulnar Fractures Improved by Dose Reduction of Adefovir and Supplementation of Oral Phosphate"},{"@value":"今月の症例 adefovirの減量と経口リン製剤が有効であった病的尺骨骨折を伴うFanconi症候群の1例"},{"@language":"ja-Kana","@value":"コンゲツ ノ ショウレイ adefovir ノ ゲンリョウ ト ケイコウ リン セイザイ ガ ユウコウ デ アッタ ビョウテキ シャッコツ コッセツ オ トモナウ Fanconi ショウコウグン ノ 1レイ"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1111/j.1440-1746.2008.05760.x"},{"@type":"OPENAIRE","@value":"doi_dedup___::b8323bb7d378a7cc936cbd3693c55296"},{"@type":"CROSSREF","@value":"10.2957/kanzo.56.482_references_DOI_PSYgsEFoBnWJrVbliRZeVOO35iK"},{"@type":"CROSSREF","@value":"10.1182/asheducation-2014.1.576_references_DOI_PSYgsEFoBnWJrVbliRZeVOO35iK"},{"@type":"CROSSREF","@value":"10.1111/hepr.12269_references_DOI_PSYgsEFoBnWJrVbliRZeVOO35iK"},{"@type":"CROSSREF","@value":"10.1111/j.1872-034x.2011.00807.x_references_DOI_PSYgsEFoBnWJrVbliRZeVOO35iK"},{"@type":"CROSSREF","@value":"10.2957/kanzo.54.402_references_DOI_PSYgsEFoBnWJrVbliRZeVOO35iK"},{"@type":"CROSSREF","@value":"10.2169/naika.103.1927_references_DOI_PSYgsEFoBnWJrVbliRZeVOO35iK"}]}